VPI is a technology company LICENSING the gene therapy industry's only user-friendly STABLE lentiviral vector PRODUCER CELL LINE manufacturing PLATFORM.
We will TEACH YOU using a DEFINED, COMMERCIALLY READY PROCESS and a set of UNIQUE REAGENT CELL LINES, to generate banks of OPTIMALLY PERFORMING stable lines from ANY third generation SIN lentiviral backbone using ANY pseudotype.
Michael Greene, MD
MEET THE FOUNDER
Mike Greene is a pioneering gene therapist whose work over the last three decades in biological research, clinical medicine, and the pharma industry, has contributed to multiple breakthrough therapies, including Kymriah, the first FDA-approved gene therapy. Known for his ability to see around corners and unite diverse teams, he has consistently delivered innovation where the stakes are highest. He is inviting leaders and advocates across science, medicine, and industry to join him and his team at VPI in their mission to expand patient access, facilitate the development programs of the future, and assure that NO patients are left waiting for a cure.
Frequently Asked Questions
What is a stable producer cell line?
An engineered HEK293T cell line containing all the necessary genetic elements to allow plasmid-free manufacturing at scale.
All of VPI's lines are commercially GMP compliant and grow in suspension using defined media.
What is the expected titer?
A stable cell line is not magic, it will not make a bad vector into a good vector, but it will make a difficult to manufacture vector easy, scalable, and plasmid-free.
Our OPTIMAL stable PLATFORM process should generate at least 2x your lab-scale transient titer, with results of 5x to 10x lab scale transient possible at full production scales, regardless of transgene size or complexity.
So, I can expect 10x more functional vector particles per batch with stables?
No. Manufacturing with stables unlocks MULTIPLE HARVESTS per run (5-7x vs 1-2x), so you should expect 10x - 70x FUNCTIONAL VECTOR TITER PER BATCH versus traditional transients.
I represent a CDMO rather than a drug company, would VPI train a competitor?
VPI believes the entire field needs to pivot to stable manufacturing immediately to alleviate the VECTOR CRISIS and free up manufacturing capacity globally. This is already WAY BIGGER than one company.
That said, VPl is NOT a CDMO, we are a technology company. We view all vector manufacturers and drug manufacturers using vectors as our peers and potential clients.
Published Research:
Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection
Blood. 2009 Mar 13;113(21).
Transduction of Human CD34+ Repopulating Cells with a Self-Inactivating Lentiviral Vector for SCID-X1 Produced at Clinical Scale by a Stable Cell Line
Hum Gene Therapy Methods. 2012 Sep 11;23(5).
PROGRAM PRICING
Three Development Tiers
Stable cell line manufacturing is a high margin business due to the profound value they impart to a drug program. An early pivot to stable manufacturing will save between $4-7 billion dollars (USD) PER DRUG.
#1
#2
#3
Our team is ready for you. Let’s innovate and optimize your vector process.